Erdem, Semiha BahceciGenel, FerahNacaroglu, Hikmet TekinKaraman, SaitKarkiner, Canan Sule UnsalSurucu, MuratCan, Demet2024-03-092024-03-0920230301-05461578-1267https://doi.org/10.15586/aei.v51i3.797https://hdl.handle.net/20.500.14034/1435Background: Food allergy (FA), hence the incidence of food anaphylaxis, is a public health problem that has increased in recent years. There are still no biomarkers for patients with FA to predict severe allergic reactions such as anaphylaxis. Objective: There is limited information on whether regulatory T (Treg) cell levels are a biomarker that predicts clinical severity in cases presenting with FA, and which patients are at a greater risk for anaphylaxis. Methods: A total of 70 children were included in the study: 25 who had IgE-mediated cow's milk protein allergy (CMPA) and presented with non-anaphylactic symptoms (FA/A-), 16 who had IgE-mediated CMPA and presented with anaphylaxis (FA/A+) (a total of 41 FA cases), and a control group consisting of 29 children without FA. The study was conducted by performing CD4+CD25+CD127(lo)FOXP3+ cell flow cytometric analysis during resting at least 2 weeks after the elimination diet to FA subjects. Results: When the FA group was compared with healthy control subjects, CD4+CD25+CD127(lo)FOXP3+ cell rates were found to be significantly lower in the FA group (p < 0.001). When the FA/A- and FA/A+ groups and the control group were compared in terms of CD4+CD25+CD127(lo)FOXP3+ cell ratios, they were significantly lower in the FA/A- and FA/A+ groups compared to the control group (p < 0.001). Conclusions: Although there was no significant difference between the FA/A+ group and the FA/ A- group in terms of CD4+CD25+CD127(lo)FOXP3+ cells, our study is important, as it is the first pediatric study we know to investigate whether CD4+CD25+CD127(lo)FOXP3+ cells in FA predict anaphylaxis. (c) 2023 Codon Publications. Published by Codon Publications.eninfo:eu-repo/semantics/openAccessFoxp3; Treg Cells; Children; Food Allergy; Cow's Milk Protein Allergy; AnaphylaxisArticle10.15586/aei.v51i3.797513814N/AWOS:0010368441000022-s2.0-8515891532537169554Q3